Sen. Grassley To Be "More Insistent" About Drug Firms' Testimony At Future Hearings
“I want to express my displeasure at the lack of cooperation from the pharmaceutical manufacturers recently,” Finance Committee chair says, noting that large firms had declined invitations to speak publicly.
You may also be interested in...
Letters to Lilly, Novo Nordisk and Sanofi signal potential next avenue for Finance Committee's investigation after CEO hearing on Tuesday.
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
President Trump’s 2019 State of the Union Address broadly touched on the themes of funding childhood cancer research, drug pricing and eliminating HIV.